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of Messina, Messina, Italy, 3Department of Medicine, University of Kentucky, Lexington, KY, United States, 4Department for
Health Promotion and Mother-Child Care, University of Palermo, Palermo, Italy
Objective: Coronavirus disease 2019 (COVID-19) is a disease with a high rate of
progression to critical illness. However, the stratification of patients at risk of mortality
is not well defined. In this study, we aimed to define a mortality risk index to allocate
patients to the appropriate intensity of care.
Methods: This is a 12 months observational longitudinal study designed to develop and
validate a pragmatic mortality risk score to stratify COVID-19 patients aged ≥18 years
and admitted to hospital between March 2020 and March 2021. Main outcome was
in-hospital mortality.
Results: 244 patients were included in the study (mortality rate 29.9%). The Covid-19
Assessment for Survival at Admission (CASA) index included seven variables readily
available at admission: respiratory rate, troponin, albumin, CKD-EPI, white blood cell
count, D-dimer, Pa02/Fi02. The CASA index showed high discrimination for mortality with
an AUC of 0.91 (sensitivity 98.6%; specificity 69%) and a better performance compared
to SOFA (AUC = 0.76), age (AUC = 0.76) and 4C mortality (AUC = 0.82). The cut-off
identified (11.994) for CASA index showed a negative predictive value of 99.16% and a
positive predictive value of 57.58%.
Conclusions: A quick and readily available index has been identified to help clinicians
stratify COVID-19 patients according to the appropriate intensity of care and minimize
hospital admission to patients at high risk of mortality.
Keywords: COVID-19, outcome research, mortality risk, stratification index, systemic score
INTRODUCTION
Since the outbreak in Wuhan city, China on December 2019 of a viral pneumonia
with an unidentified etiology (1), a novel strain of coronavirus was isolated and
defined Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) by the
Coronaviridae Study Group (CSG) of the International Committee on Taxonomy of Viruses
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(2). COVID-19 became the name of the disease that is induced
by the aforementioned virus, which has caused a global pandemic
accounting, as of May 8th 2021, for more than 3.2 million deaths
worldwide as reported by WHO.
After more than one year from the original Chinese outbreak,
national health systems are still facing devasting consequences
due to the poor ability to control infection spreading and
slow adaptation to the high number of hospital admissions. A
lack of ability to easily stratify the patients on the first day
of admission has further hampered efforts to influence the
rate of mortality. Currently the overwhelming number of Sars-
Cov-2 infected patients requiring hospitalization outpaces the
availability of human and medical resources in several countries.
All these conditions argue for the definition of a very high
performing, predictive index ofmortality to allow the appropriate
allocation of COVID-19 resources (3). For maximum utility such
an index would be constructed from elements of clinical and
laboratory features available on the first day of hospitalization
and applicable as a guide to reorganize dedicated COVID-
19 divisions according to disease severity at admission and
mortality risk (4). Paradoxically, identifying patients occupying
the opposite end of the disease severity spectrum – those with
very low or perhaps even no risk – can be equally useful to
resource allocation. Clinicians and health care systems urgently
warrant reliable scores to identify those patients with COVID-19
at highest risk for death requiring admission, to stratify them in
the appropriate level of care and apply a rational optimization of
resources. In addition, these instruments can also help clinician
adopt quick and reliable clinical decisions and anticipate the
prognosis to patients and their families.
Despite in the early phase of pandemic several other COVID-
19 and non-COVID-19 specific scores have been employed in
an attempt to stratify according to mortality or ICU admission
risk, validation studies failed to confirm their applicability in
larger populations (5–15). According to a recent review article
analyzing the existing scores predicting COVID-19 mortality,
the 4C mortality score, designed specifically for COVID-
19, is likely to have the best performance, though it has
intrinsic limitations and a relatively low positive predictive
value (16–18).
Our aim was, then, to identify a COVID-19 specific score to
predict mortality with improved positive predictive value and
comparable very high negative predictive value, thus reducing
the number of COVID-19 patients requiring medium-high
intensity of care and concentrating patients at risk of mortality
in adequately skilled and equipped divisions. Early stratification
of patients who are either highly prone to develop critical disease,
or are substantially protected from it, is of undoubted importance
in guiding the clinician in delivering proper care and optimizing
use of limited health resources.
Thus, we aimed to build a mortality risk prediction score
for an ascertainment set of consecutive patients with COVID-19
and radiologic evidence of pneumonia based entirely upon data
available on the day of admission.
MATERIALS AND METHODS
This is a single center, longitudinal, observational study involving
consecutive admitted patients aged ≥18 years and diagnosed
with Sars-Cov-2 infection and radiologic evidence of pulmonary
involvement. The study enrollment period was 1 year time from
March 2020 to March 2021 in the critical medicine division of
the University of Messina. Patients directly admitted in ICU were
not included in our study. In addition, we excluded patients
who were either admitted with non-COVID-19 symptoms
and had incidental asymptomatic diagnosis (e.g. hip fracture
without clinical features of COVID-19), those admitted for
isolation/control reasons, and also those with COVID-19 who
were discharged from either ambulatory care or the emergency
room, without admission. Among 249 eligible patients, 5 were
excluded due to missing data at admission. A total of 244 patients
with confirmed Sars-Cov-2 infection and radiologic evidence
of pulmonary involvement were thus enrolled in the study.
Oropharyngeal and nasal swab samples were taken from all
patients upon hospital admission. Patients with a positive result
of swabs, confirmed by real time reverse transcriptase polymerase
chain reaction, and radiologic evidence of pneumonia were
included in the study. The studywas approved by the institutional
review board of the University of Messina and informed consent
was obtained from all subjects. They all agreed to routine access
to their record and analysis of their medical history data at the
time of admission.
Data Collection
The demographic (age, sex, home isolation, in-hospital stay,
smoking exposure, body mass index and comorbidity), clinical
(vital parameters and signs/symptoms), laboratory parameters
at admission, Ordinal Scale for Clinical Improvement
(19), therapeutic regimen and the final outcomes (the
deceased/survivors, ICU transfer) of the enrolled patients were
prospectively collected. The following new onset signs/symptoms
were included: fever, cough, shortness of breath, confusional state
and Coma Glasgow Scale, diarrhea, fatigue, headache, nausea or
vomiting, sore throat, sputum production, arthralgia or myalgia.
Comorbidities collected were: chronic cardiac disease, chronic
respiratory disease, chronic renal disease, dementia, chronic
neurological conditions, connective tissue disease, thyroid
disease, diabetes mellitus and malignancy.
The laboratory parameters included were: hemoglobin,
platelet count, red cell count, white cell count, lymphocyte
count, hematocrit (HCT), C-reactive protein (CRP),
procalcitonin, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), lactate dehydrogenase (LDH), albumin,
ferritin, fibrinogen, urea, creatinine, Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation (CKD-epi) for
the assessment of Estimated glomerular filtration rate troponin,
NT-Pro-BNP and D-dimer, PaO2/FiO2 ratio. The clinical
information used to calculate prognostic scores was taken from
the day of hospital admission.
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Outcomes
The primary outcome of the study was in-hospital mortality. This
outcome was selected because of its face validity. We considered
of primary interest the stratification of patients according to the
mortality risk in order to be able to escalate intensity of care and
therapeutic regimen for patients likely to develop severe illness
from SARS-CoV-2 infection.
Independent Predictor Variables
A reduced set of potential predictor variables was selected a
priori, including patient demographic information, common
clinical investigations, and parameters consistently identified
as clinically important in COVID-19 cohorts, as previously
reported (20).
Candidate predictor variables were selected based on two
common criteria: variables known to influence outcome in
pneumonia and flulike illness; clinical biomarkers previously
identified within the literature as potential predictors in patients
with COVID-19 (21–23).
Statistical Analysis and Model
Development
Continuous and categorical variables were presented as median
(IQR) and n (%), respectively.We used theMann-Whitney U test
or Fisher’s exact test to compare differences between survivors
and non-survivors where appropriate.
The primary intention was to create a pragmatic model for
use during admission to stratify patients for intensity of care,
maximizing for sensitivity and specificity in order to exclude
those not requiring a medium-high intensity of care. We used
the following steps to build the model: firstly, univariable logistic
regression analysis was performed for all the variables that
were significant in the between-group analysis. Since age was
independently associated with the outcome of interest (the
deceased vs. survivors), we performed age-adjusted univariable
logistic regression for the variables significant in the first round
of univariable logistic regression analysis after categorizing
them according to laboratory reference range or clinical criteria
where appropriate.
To enhance a pragmatic approach, the significant age-adjusted
variables were plotted in their categorized form, according to
the reference range of the test (present/absent), in multivariable
logistic regression analysis with backward stepwise method.
The model retained 7 variables, thus minimizing the risk of
overfitting according to the number of events occurred (n =
73). A score was then created by multiplying the odds ratio of
each relevant variable. Receiver operating characteristics (ROC)
curves were used to assess the accuracy of model predictions and
area under curve (AUC) with negative predictive value (NPV),
positive predictive value (PPV), specificity and sensitivity was
given and compared to the results of age, SOFA and 4C mortality
scores according to De Long et al. (24).
RESULTS
Demographics characteristics, vital parameters, clinical features
and comorbidities at admission for the entire study population
and for the group of deceased patients (73) and survivors (n =
171) are collected in Table 1, while Table 2 shows the laboratory
results. The mortality rate of our study population was 29.9%,
while 13.5% were transferred in ICU. Patients were treated
with the following medications: 87% with corticosteroids, 85%
with heparin, 16% with hydroxychloroquine. No patients were
treated with remdesivir, tocilizumab, plasma hyperimmune or
monoclonal antibodies.
Comparison of Demographics and Clinical
Characteristics Between Survivors and
Deceased Patients at Admission
As initial analysis, we sought to compare the profile of patients
according to the outcome of interest. Among the demographic
features, deceased patients were older, while no differences were
observed in gender prevalence or BMI between the groups. Next,
we analyzed the differences in the prevalence of comorbidities
between survivors and deceased. History of chronic kidney
disease, coronary artery disease and heart failure were more
frequent in deceased patients, while no differences were found
for hypertension or diabetes prevalence. Neurologic features
were also significantly different between survivors and deceased:
both dementia and cerebrovascular disease prevalence were
significantly higher in the deceased groups and, accordingly, new
onset confusional state and lower Glasgow Coma Scale were
more frequently identified in the group of deceased patients.
In addition, while a positive history of COPD or respiratory
failure was not more frequent in deceased patients, both a
higher respiratory rate and the presence of shortness of breath at
admission were common features in deceased patients compared
to survivors. On the contrary, the presence of arthralgia or
myalgia is a common finding in subjects who survive.
Comparison of Laboratory Results
Between Survivors and Deceased Patients
at Admission
Initially, we evaluated the laboratory results at admission of the
groups to identify the relevant discriminants of deceased patients.
The subjects belonging to each group were then categorized
according to the cut-off laboratory reference. In accordance
with the comorbidities profile, a higher prevalence of chronic
kidney disease, heart failure and coronary artery disease in
deceased patients corresponded to a higher troponin T and
NT-PRO-BNP levels and also higher urea and creatinine levels
with concomitant lower CKD-EPI compared to survivors. In
addition, both low platelet count and high white blood cell
count and procalcitonin levels were more common in deceased
patients compared to survivors with no difference in lymphocytes
levels. On the contrary, low white blood cells count was more
common in survivors compared to deceased patients. Among
the inflammatory markers both CRP and fibrinogen were
significantly higher in the deceased group, while no between-
group difference was found in ferritin levels. Furthermore,
albumin, D-Dimer, LDH and AST levels were significantly higher
in deceased patients, while ALT and total bilirubin levels were not
different between deceased and survivors.
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TABLE 1 | Demographic and clinical features of COVID-19 patients at admission.
Total
(n = 244)
Deceased
(n = 73)
Survivors
(n = 171)
p
Demographics
Age, median (IQR) 72.3 (24.9) 79.7 (12.7) 69 (23.08) < 0.001
Over 65 years, n (%) 155 (67.6) 66 (90.4) 99 (57.9) < 0.001
BMI, median (IQR) 25.4 (4.6) 25.7 (5.2) 25.2 (4.7) 0.228
Home isolation, days 1 (3.8) 0 (2.5) 1 (4) 0.518
Smoking, current 35 (14.3) 9 (12.3) 26 (15.2) 0.356
Smoking, past 29 (11.9) 14 (19.1) 30 (17.4) 0.761
Gender, male 135 (55.3) 38 (52) 97 (56.7) 0.297
Comorbidities
Dementia 70 (28.6) 30 (41) 36 (21) < 0.001
Diabetes 70 (28.6) 24 (32.8) 46 (26.9) 0.214
Asthma 3 (1.2) 3 (1.7) 0 (0) 0.342
Autoimmune diseases 4 (2) 1 (1.3) 4 (2.3) 0.529
Coronary artery disease 51 (20.9) 21 (28.7) 30 (17.5) 0.038
Myocardial infarction 10 (4) 4 (5.4) 6 (3.5) 0.346
COPD 28 (11.4) 8 (10.9) 20 (11.7) 0.531
Heart failure 44 (18) 20 (27.4) 24 (14) 0.012
Hypertension 155 (63.5) 46 (63) 109 (63.7) 0.513
Malignancy 23 (9.4) 10 (13.7) 13 (7.6) 0.107
Chronic kidney disease 74 (30.3) 40 (54.8) 34 (19.8) < 0.001
Stroke 11 (4.5) 6 (8.2) 5 (2.9) 0.0801
Cerebrovascular disease 43 (17.6) 19 (26) 24 (14) 0.021
Thyroid disease 12 (4.9) 6 (8.2) 6 (3.5) 0.271
Respiratory failure 12 (4.9) 4 (5.4) 8 (4.6) 0.507
Clinical presentation
Confusional state 58 (23.7) 24 (32.8) 34 (19.8) 0.023
Cough 101 (41.4) 28 (38.3) 73 (42.7) 0.314
Diarrhea 20 (8.2) 5 (6.8) 15 (8.7) 0.414
Fatigue 126 (51.6) 32 (43.8) 94 (54.9) 0.073
Fever 99 (40.5) 30 (41) 69 (40.3) 0.512
Headache 45 (18.4) 9 (12.3) 36 (21) 0.074
Nausea or vomiting 27 (11) 9 (12.3) 18 (10.5) 0.505
Shortness of breath 132 (54) 55 (75.3) 77 (45) < 0.001
Sore throat 59 (24.1) 19 (26) 40 (23.4) 0.451
Sputum production 25 (10.2) 9 (12.3) 16 (9.3) 0.120
Arthrlagia or myalgia 65 (26.6) 9 (12.3) 56 (32.7) 0.001
OSCI 5.1 (0.8) 5.3 (1.3) 4.9 (0.9) 0.437
Vital parameters
Heart rate 80 (17.5) 80 (23) 80 (14) 0.068
DBP, mmHg 70 (20) 70 (20) 70 (16) 0.355
SBP, mmHg 130 (35) 125 (40) 130 (35) 0.541
MBP, mmHg 90 (21.5) 88 (25) 91 (21) 0.402
Respiratory Rate 18 (6) 24 (7) 18 (4) < 0.001
Respiratory Rate >20 82 (33.6) 50 (68.5) 32 (18.7) < 0.001
CGS 15 (2) 13 (4) 15 (0) < 0.001
CGS, Coma Glasgow Scale; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; MBP, Medium Blood Pressure; BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary
Disease; OSCI, Ordinal Scale for Clinical Improvement.
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TABLE 2 | Laboratory results in COVID-19 patients at admission.
Total Deceased Survivors
(n = 244) (n = 73) (n = 171) p
Laboratory results
Albumin, g/dL 3.07 (0.8) 2.7 (0.6) 3.21 (0.6) < 0.001
Albumin ≤ 2.5 18 (7.7) 15 (21.4) 3 (1.8) < 0.001
ALT, UI/L 21 (20.5) 23 (24) 20 (17) 0.084
AST, UI/L 26 (20.8) 33 (29) 24 (15) < 0.001
AST ≥ 42 52 (21.3) 26 (35.6) 26 (15.2) 0.001
CKD-EPI, ml/min 71.9 (50.1) 43.5 (64.5) 79.1 (36.5) < 0.001
CKD-EPI ≤ 60 94 (38.5) 48 (65.7) 46 (26.9) < 0.001
CK, U/L 99 (195) 99 (301) 100 (184) 0.177
Creatinin, mg/dL 1 (0.7) 1.3 (1.4) 0.9 (0.5) < 0.001
Creatinin ≥ 1.2 77 (31.5) 38 (22) 39 (53.4) < 0.001
D-Dimer, mcg/mL 1 (1.5) 1.86 (3.2) 0.84 (1) < 0.001
D-Dimer ≥ 4 33 (13.6) 24 (33) 9 (5.2) < 0.001
LDH, U/L 444.5 (324) 678.5 (596.5) 403 (196.3) < 0.001
LDH ≥ 450 114 (46.7) 53 (72.6) 61 (35.7) 0.081
NT-PRO-BNP, pg/mL 433.5 (2082.5) 2748.5 (7901) 229.5 (690.3) < 0.001
NT-PRO-BNP ≥ 125 149 (61) 64 (87.6) 112 (65.4) < 0.001
Ferritin, ng/mL 621 (678) 785 (773) 487 (676) 0.046
Ferritin ≥ 300 180 (73) 69 (94.5) 117 (68) 0.018
Fibrinogen, mg/dL 527 (253) 562 (274) 515 (216) 0.017
Fibrnogen ≥ 400 192 (78.6) 61 (83.5) 131 (76.3) 0.173
Hb, gr/dL 12.9 (2.8) 12.2 (3.5) 13 (2.4) 0.295
PaO2/FiO2 ratio 295.2 (160.9) 209.2 (213.4) 319 (126) < 0.001
PaO2/FiO2 ≤ 300 128 (52.4) 54 (73.9) 74 (43.2) < 0.001
CRP, mg/dL 4.19 (10.2) 10.76 (14) 2.69 (6.2) < 0.001
CRP ≥ 0.5 198 (81.1) 67 (91.7) 131 (76.6) < 0.001
PCT, ng/mL 0.11 (0.22) 0.31 (1.13) 0.8 (0.11) 0.002
PCT ≥ 0.5 44 (18) 30 (41) 14 (8) < 0.001
PLT, cells x 104 20.9 (11.6) 16.6 (16.2) 21.3 (10.8) < 0.001
PLT ≤ 15 ×104 51 (20.9) 21 (28.7) 30 (17.5) 0.038
Total bilirubin, mg/dL 0.52 (0.5) 0.69 (0.7) 0.51 (0.4) 0.131
Troponin, pg/mL 26.5 (48) 60 (129.5) 18 (23.9) < 0.001
Troponin ≥ 14 170 (69.6) 66 (90.4) 104 (60.8) < 0.001
Urea, mg/dL 49 (46) 79.5 (75.5) 40 (28) < 0.001
Urea ≥ 50 115 (47.3) 55 (75.3) 60 (35) < 0.001
WBC, cells x 103 7.5 (6.1) 10.5 (7) 6.7 (4.2) < 0.001
WBC ≤ 4x103 29 (11.9) 4 (5.4) 25 (14.6) 0.030
WBC ≥ 10x103 78 (32) 40 (54.8) 38 (22.2) < 0.001
Lymphocyte count 1269.5 (880.8) 1,176 (794) 1,300 (883) 0.386
Data are expressed as median (interquartile range) or number (percentages) accordingly. WBC, white blood cells; PLT, platelet cells; PCT, procalcitonin; Hb, haemoglobin; CRP, C-reactive
protein; NT-PRO-BNP, N-terminal pro-brain natriuretic peptide; LDH, lactate dehydrogenase; CK, creatine kinase; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; AST,
aspartate transaminase; ALT, Alanine transaminase.
Age-Adjusted Univariable Logistic
Regression Analysis and Multivariable
Model Definition
After identifying the factors that were statistically significant
in the deceased group, univariable logistic regression analysis
was performed after adjusting for age, as it resulted to be the
unique significantly different variable among the demographic
characteristics of our study population (Table 3). After adjusting
for age, only history of chronic kidney disease remained
significant among comorbidities, while age correction did not
affect the significance of the factors belonging to clinical
presentation and vital parameters. Laboratory results remained
all significant apart from NT-PRO-BNP. After ruling out
variables from the multivariable analysis according to the
differences between-group (Tables 1, 2), we further excluded
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TABLE 3 | Age-adjusted univariable logistic regression analysis for mortality risk.
OR (95%CI) p
Heart failure 0.599
Coronary artery disease 0.363
Chronic kidney disease 2.96 (1.56–5.63) 0.001
Cerebrovascular disease 0.079
Stroke 0.175
Dementia 0.818
Confusional state 0.243
CGS 0.091
Shortness of breath 3.96 (2.03–7.73) < 0.001
Respiratory Rate > 20 bpm 8 (4.08–15.69) < 0.001
Albumin < 2.5 g/dL 14.72 (3.43–63.25) < 0.001
AST > 42 U/I 2.62 (1.31–5.25) 0.006
CKD-EPI < 60 ml/min 5.22 (2.89–9.41) < 0.001
Creatinin > 1.2 mg/dL 2.44 (1.29–4.60) 0.006
D-Dimer > 4 mcg/mL 5.57 (2.31–13.40) < 0.001
NT-PRO-BNP > 125 pg/mL 0.092
PaO2/FiO2 < 300 3.18 (1,65–6,15) 0.001
CRP > 0.5 mg/dL 5.47 (1.79–16.72) 0.003
PLT < 15 × 104 cells 3.5 (1.76–6.94) 0.008
Troponin T > 14 pg/mL 5.15 (1.42–18.62) 0.002
Urea > 50 mg/dL 3.67 (1.9–7.08) < 0.001
WBC > 10 × 103 cells 4.39 (2.29–8.42) < 0.001
Data are expressed as median (interquartile range) or number (percentages) accordingly.
WBC, white blood cells; PLT, platelet cells; PCT, procalcitonin; Hb, hemoglobin; CRP,
C-reactive protein; NT-PRO-BNP, N-terminal pro-brain natriuretic peptide; CKD-EPI,
Chronic Kidney Disease Epidemiology Collaboration; AST, aspartate transaminase; ALT,
Alanine transaminase; CGS, Coma Glasgow scale; bpm: breaths per minute.
those variables from the multivariable analysis if they had
multicollinearity (urea, creatinine and history of CKD, shortness
of breath). Next, we compared the difference between deceased
and survivors according to the variables significant in age-
adjusted univariable logistic regression by classifying them in
binary format according to the laboratory reference range
(respiratory rate >20 breaths per minute, albumin ≤2.5 g/dL,
d-dimer ≥4 mcg/mL, PaO2/FiO2 ratio ≤300, AST ≥42 UI/L,
CKD-EPI ≤60 ml/min, CRP ≥0.5 mg/dL, PLT ≤ 15 × 104,
WBC ≥10 × 103, troponin ≥14 pg/mL). Thus, among the 10
variables from the age-adjusted univariable analysis included in
the model, the multivariable logistic regression analysis with
conditional step-wise backward method retained 7 variables:
respiratory rate >20 breaths per minute, albumin ≤2.5 g/dL,
D-dimer ≥4 mcg/mL, PaO2/FiO2 ratio ≤300, CKD-EPI ≤60
ml/min, WBC ≥10 × 103, troponin ≥14 pg/mL. Table 4 show
the results of the multivariable logistic regression analysis and it
reports the 7 variables included in the index.
Score Identification and Performance
Comparison With SOFA, 4C Mortality and
Age
The predictor of mortality score, hereafter CASA (Covid-19
Assessment for Survival at Admission) index, was thus identified
TABLE 4 | Multivariable logistic regression analysis for mortality prediction.
OR (95% CI) p
Albumin < 2.5 g/dL 11.577 (1.83–73.12) 0.009
D-dimer > 4 mcg/mL 3.947 (1.12–12.99) 0.024
PaO2/FiO2 < 300 3.437 (1.38–8.56) 0.008
Troponin T > 14 pg/mL 9.851 (2.27–42.76) 0.002
WBC > 10 × 103 cells 2.708 (1.09–6.74) 0.032
Respiratory rate > 20 3.406 (1.43–8.11) 0.006
CKD-EPI < 60 ml/min 2.143 (1.24–5.21) 0.036
Data are expressed as median (interquartile range) or number (percentages) accordingly.
WBC, white blood cells; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
by multiplying each variable with the odds ratio derived from
the multivariable analysis according to the following formula:
Albumin ≤ 2.5 × 11.577 + D-Dimer ≥4 × 3.947 + P/F ≤300
× 3.437 + Troponin ≥14 × 9.851 + WBC ≥ 10,000 × 2.708 +
Respiratory rate ≥20 × 3.406 + CKD-EPI ≤60 ml/min × 2.143.
The index showed a high performance with an AUC of 0.91 (95%
CI: 0.87 – 0.95), and a sensitivity of 98.6% (95% CI: 92.6 – 99.9),
specificity of 69% (95%CI: 61.5 – 75.8) (Supplementary Table 1).
The performance of CASA index was significantly superior to
each variable analyzed singularly, as compared by AUC. In order
to validate the performance of the CASA index, we compared
it to the performance of age (AUC = 0.76; 95% CI: 0.69–0.82)
and other validated scores, such as SOFA (AUC = 0.76; 95% CI:
0.70–0.83) and 4C mortality (AUC = 0.82; 95% CI: 0.77–0.87)
(Figure 1A). After maximizing for sensitivity and specificity we
identified that a CASA index score ≥11.994 had a NPV 99.16%
(95% CI: 94.4–99.9%) and a PPV 57.58% (95% CI: 52–63%).
Next, we compared the NPV and PPV for each score and we
observed that the CASA index had the best AUC performance
compared to SOFA (p< 0.005), age (p< 0.0001) and 4c mortality
(p < 0.0001) (Figure 1B).
DISCUSSION
After more than 1 year from the onset of the pandemic and the
appearance of SARS-COV-2 variants, despite the attempts to start
intense vaccination programs, the management of COVID-19
mortality still remains imperfect.
In the balance between rate of admission, mortality risk and
disease progression toward severe acute respiratory and multi-
organ failure it appears crucial to identify and stratify patients.
If highly accurate, such stratification will help to compensate
for the uncontrolled virus contagiousness and to prepare highly
equipped division for patients needing multi-organ support.
Herein, aiming at stratifying patients for mortality risk at
admission, we have developed the seven variables CASA index
score in an Italian prospective cohort study involving 244 patients
consecutively admitted to the hospital with COVID-19 over
12 months. The CASA index employs only clinical and blood
parameters that are commonly available at the time of hospital
admission to predict mortality. In addition, the definition of the
relevant parameters that increase the risk of mortality has been
supported by age-adjustment in our study. While it is widely
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FIGURE 1 | (A,B) The figure shows in (A) the receiver operating characteristics (ROC) curves for the performance of CASA index, SOFA, 4C mortality and age in
predicting mortality in COVID-19 patients at admission. Positive and negative predictive values according to the reference cut-off are reported in (B) for the
abovementioned scores.
accepted that older age increases the risk of mortality (25, 26),
age alone is not sufficient to stratify patients for intensity of care,
while, on the other hand, age remains the main demographic
characteristic to consider when building a score for COVID-19.
The identification of patients at risk of mortality is particularly
challenging due to the onset of systemic complications of
COVID-19 and the evolution toward acute respiratory distress
syndrome (ARDS). Traditionally, ARDS presents non-specific
manifestations though it should be suspected in those presenting
progressive symptoms of respiratory distress, an increasing
requirement for oxygen, and alveolar infiltrates on chest imaging.
However, several reports suggest that COVID-19 related ARDS
is atypical (27–29), mostly due to the discrepancies between
blood gas, peripheral saturation (SpO2), lung compliance and the
occurrence of systemic complications. Indeed, SpO2 alone might
be misleading in assessing COVID-19 pneumonia evolution
due to the evidence that these patients present depressed PaO2
values with satisfactory SpO2. This has been defined as “happy”
or silent hypoxia, which might lead to an underestimation
of the disease severity and influence the clinical decision of
the appropriate admission allocation and/or delay intensive
treatment (30). Silent hypoxemia is better identified by a
significantly increased respiratory rate, which in contrast to
hypercapnia that generates dyspnea, seems to not induce
dyspnea. This could be due to a possible damage to the afferent
hypoxia-sensing neurons, induced by the intense cytokine storm
or the direct effect of SARS-CoV-2 (31–34). Compared to
lower commonly employed PaO2/FiO2 value ≤200 or less, in
an attempt to identify more patients in an early phase of
disease progression, we included in our index a PaO2/FiO2
value ≤300, as supported by the “Berlin definition” of acute
respiratory distress (34, 35). Signs of respiratory distress, such
as tachypnea, and worsening PaO2/FiO2 were included in our
index as they revealed to be independent predictors of mortality.
Hence, these factors should be closely monitored, as a sudden
and rapidly evolving disease can involve patients in stable
conditions (36).
Apart from the lung-specific alterations, several other
systemic complications have been reported in severe cases of
COVID-19. The interactions between the cardiovascular system,
the pulmonary system and kidney function in fatal cases of
COVID-19 are complex and multifaceted and also influenced
by the activation of the immune system and the coagulation
cascade (37). Preexisting coronary artery disease has been
frequently observed in fatal cases of COVID-19 and increased
troponin levels have been identified as an independent predictor
of mortality (38). In COVID-19 the mechanism of troponin
elevation is not fully understood, since it might be related to
both ischemic injury, less frequently, and non-ischemic damage,
such as pneumonia, sepsis, myocarditis, systemic inflammation,
pulmonary thrombosis and cardiac adrenergic hyperstimulation
during cytokine storm (39). Several reports confirm that all
causes of troponin levels elevation are related with the severity
of COVID-19 infection and, of note, with disease progression to
major complications like multi-organ failure and death (40). In
line with previous studies, our results show that normal cardiac
troponin levels at admission have a very high negative predictive
value for all causes of in-hospital mortality and are a very strong
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and independent indicators of hospital survival in COVID-19
patients (41). On the other hand, we hypothesize that a high
level on admission may help us identify and stratify the subgroup
of patients who may progress toward severe complications
and death.
To further confirm the complexity of the systemic alterations
involving the cardiocirculatory system, several reports suggest
that a depressed kidney function at admission, identified
by a glomerular filtration rate <60 ml/min, represents an
independent predictor of mortality (42), and this also is
evidenced by our results. The hematological profile in COVID-
19 has been regularly associated with a hypercoagulable status
with elevated D-dimer, which in turn might worsen vital
organ function (43), and contributes to the development of
complications such as ARDS, ICU access, and death (44).
The correct identification of COVID-19 subgroups prone to
develop either systemic thromboembolism, often associated
with a strong immunoinflammatory response (45), or localized
forms of coagulopathy, such as the “pulmonary intravascular
coagulopathy” (46), remains difficult. Still, the uncontrolled
activation of the coagulation system is one of the unique
mainstem of COVID-19, leading to increased mortality (29).
In addition, another hematological aspect has emerged in our
analysis. While lymphopenia has been invariably linked to the
disease itself irrespective of the severity status, leucocytosis is
common in patients with aggressive evolution (47), thus adding
the disruption of the immune system associated with possible
bacterial infection as an additional mortality risk factor, and
supporting the relevance of a dynamic monitoring for the early
identification of white blood cell increase (48).
Finally, several reports suggest that albumin levels are
inversely correlated with the white blood cell count, suggesting
that the dysregulated immune response causes an augmented
capillary permeability and an extravasation of serum albumin
into the interstitial space. Infact, hypoalbuminemia has been
already reported as a marker of disease severity and increased
hospital mortality in past SARS epidemics (49). It is known
that reduced serum albumin levels are found in patients with
COVID-19 (50, 51) and in general albumin levels below 2/2.5
g/L are associated with ARDS severity (52). According to other
studies on COVID-19 patients, it has been suggested that even a
higher serum albumin level cut-off, such as 3.5 g/L at presentation
independently increases the risk of death in COVID-19 (49, 53,
54).
Our study has some limitations: firstly, we were unable to
evaluate the predictive performance of several existing scores that
require a larger number of parameters (for example, APACHE
II, PSI), as well as other COVID-19 prognostic scores that
use computed tomography findings or uncommonly measured
biomarkers. However, we were able to compare the performance
of CASA index to the COVID-19 specific 4C mortality index,
in addition to age and SOFA. Thus, by including comparisons
with pre-existing models, reassurance is provided that equivalent
performance cannot be delivered with a simple tool already in
use, or at least not one that can be applied on the first hospital
day. In addition, treatment regimen, limited by the availability
of specific emerging therapy, might have influenced the primary
outcome. The sample size involved in the study, while covering
a long-term observation, requires validation studies in other
cohorts to confirm our findings. Nevertheless, the size of our
patient cohort compares favorably to other datasets for model
creation. The patient cohort on which the 4CMortality Score was
derived also comprised patients admitted to hospital who were
seriously ill (mortality rate of 32.2%) and were of advanced age
(median age 72.3 years). Thus, the CASA index is not for use in
the community and will likely perform differently in populations
at lower risk of death. Further external validation is required to
determine whether our index is applicable in other populations.
In conclusion, there is an increased need for tools to stratify
patients for intensity of care and to specifically exclude from
medium-high intensity divisions those patients not at risk of
death. The complex systemic disturbances occurring during
COVID-19 remain difficult to ascertain, as does the practical
distinction between subjects with a self-limiting disease and those
evolving toward acute respiratory syndrome and multi-organ
failure. Our index may prove useful to stratify those who are
candidates for admission to medium-high intensity of care units
and to improve the allocation of equipment and human resources
to prepare health system to adapt according to the unpredictable
evolution of COVID-19. In addition, the CASA index, due
to its easy applicability in emergency departments, facilitates
the stratification of medium-low intensity patients to the
appropriate division by including a systemic view of the disease,
including extrapulmonary manifestations. Covering a wide range
of COVID-19 patients requiring non-ICU hospitalization, as
expressed by the Ordinal Scale for Clinical Improvement, the
CASA index might prove useful in stratifying patients to the
appropriate intensity of care and have a large-scale use due to
its quick feasibility at admission. Further validation studies are
needed to confirm the performance of the index and to test the
limits of its generalizability.
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